Dr Tony Lockett is a Visiting Lecturer in the in the Centre for Pharmaceutical Medicine Research, Institute of Pharmaceutical Science, School of Cancer & Pharmaceutical Sciences.

Dr Lockett initially trained in infectious diseases and tropical medicine in Public Health England and the London School of Hygiene and Tropical Medicine. He joined the pharmaceutical industry in 1990, where he worked in antimicrobial development for Park-Davis (now Pfizer). He left his post to complete a PhD in economics at St Andrew's University and an MBA from Henley Management College. Following his PhD, he became head of translational medicine in Covance, before joining an NIH spinout in vaccines and nanotechnology. He returned to the UK in 2009 to take the post of Chief Medical Officer at HVivo - a respiratory specialist CRO in London, and joined Kings as a Lecturer shortly thereafter.

In addition to teaching at Kings, Dr Lockett is a director of a couple of small and medium-sized enterprises in the area of antimicrobial research, one a spinout from Kings. Both of the companies he is involved in are looking at the role of biofilm penetration in overcoming anti-microbial resistance. He also has an active research interest in the ethics of global health issues such as SARS-CoV-2 and antimicrobial resistance, where he actively researches the role of justice in informed consort to research. He retains an active consultancy in anti-infective research and has been advising companies in clinical development strategies for the COVID-19 outbreak.